Roles and therapeutic implications of m6A modification in cancer immunotherapy

Pan, Juan1,2; Huang, Tuxiong3; Deng, Zhenjun4,5; Zou, Chang1,2,6

2023-03-07

10.3389/fimmu.2023.1132601

FRONTIERS IN IMMUNOLOGY   Impact Factor & Quartile

1664-3224

Recent studies have demonstrated that N6-methyladenosine (m6A), the most abundant, dynamic, and reversible epigenetic RNA modification in eukaryotes, is regulated by a series of enzymes, including methyltransferases (writers), demethylases (erasers), and m6A recognition proteins (readers). Aberrant regulation of m6A modification is pivotal for tumorigenesis, progression, invasion, metastasis, and apoptosis of malignant tumors. Immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, as recognized by the 2018 Nobel Prize in Medicine and Physiology. However, not all cancer patients response to ICI therapy, which is thought to be the result of intricate immune escape mechanisms. Recently, numerous studies have suggested a novel role for m6A epigenetic modification in the regulation of tumor immune evasion. Herein, we review the relevant mechanisms of m6A regulators in regulating various key signaling pathways in cancer biology and how m6A epigenetic modifications regulate the expression of immune checkpoints, opening a new window to understand the roles and mechanisms of m6A epigenetic modifications in regulating tumor immune evasion. In addition, we highlight the prospects and development directions of future combined immunotherapy strategies based on m6A modification targeting, providing directions for promoting the treatment outcomes of immune checkpoint inhibitors.

m6A modification cancer immune checkpoints m6A-regulator inhibitors immunotherapy

SCI

English

Corresponding

Immunology

Immunology

WOS:000950733500001

FRONTIERS MEDIA SA

Web of Science

1.Guangxi Med Univ, Natl Ctr Int Res Biotargeting Theranost, Collaborat Innovat Ctr Targeting Tumor Diag & Ther, Guangxi Key Lab Biotargeting Theranost,Guangxi Tal, Nanning, Guangxi, Peoples R China
2.Southern Univ Sci & Technol, Jinan Univ, Dept Clin Med Res Ctr, Affiliated Hosp 1,Clin Med Coll 2,Shenzhen People, Shenzhen, Peoples R China
3.Shenzhen Univ, Int Canc Ctr, Dept Pharmacol, Guangdong Prov Key Lab Reg Immun & Dis,Hlth Sci Ct, Shenzhen, Peoples R China
4.Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Dermatol, Shenzhen, Peoples R China
5.Jinan Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
6.Jinan Univ, Shenzhen Peoples Hosp, Shenzhen Publ Serv Platform Tumor Precis Med & Mol, Clin Med Coll 2, Shenzhen, Peoples R China

Pan, Juan,Huang, Tuxiong,Deng, Zhenjun,et al. Roles and therapeutic implications of m6A modification in cancer immunotherapy[J]. FRONTIERS IN IMMUNOLOGY,2023,14.

Pan, Juan,Huang, Tuxiong,Deng, Zhenjun,&Zou, Chang.(2023).Roles and therapeutic implications of m6A modification in cancer immunotherapy.FRONTIERS IN IMMUNOLOGY,14.

Pan, Juan,et al."Roles and therapeutic implications of m6A modification in cancer immunotherapy".FRONTIERS IN IMMUNOLOGY 14(2023).